Endothelial cell proliferation and extracellular matrix-related pathways regulate pulmonary arterial hypertension in rat models

doi:10.16352/j.issn.1001-6325.2025.06.0770

Abstract

Abstract: Objective To identify mechanisms regulating disease progression in rat models of pulmonary arterial hypertension (PAH). Methods Rat PAH models were established using subcutaneous monocrotaline (MCT) injection and the SU5416/hypoxia (SU/Hx) method. Transcriptomic sequencing of lung tissues was performed to identify gene expression and pathway alterations in PAH rats, followed by a comparative analysis with transcriptomic data of patients with idiopathic pulmonary arterial hypertension (IPAH) in NCBI database. Results Inflammatory-related genes such as CXCL9, CCL24, and SECTM1 were upregulated in both PAH rat models and IPAH patient lungs, while genes such as DGKG and DOCK9 were downregulated(P＜0.05). Pathways related to endothelial cell proliferation regulation and extracellular matrix (ECM) remodeling were significantly upregulated(P＜0.05). Conclusions The imbalance in endothelial cell proliferation and abnormal ECM remodeling may collectively contribute to PAH pathogenesis. Further exploration of these signaling pathways may provide deep insights for early diagnosis and targeted therapy of PAH.

Key words: pulmonary artery hypertension (PAH), animal model, endothelial cell, extracellular matrix (ECM)

CLC Number:

R543
R331.3

LU Xiaoxuan, GUO Lina, ZHANG Hong, SONG Wanlu, HU Yufei, YANG Peiran. Endothelial cell proliferation and extracellular matrix-related pathways regulate pulmonary arterial hypertension in rat models[J]. Basic & Clinical Medicine, 2025, 45(6): 770-776.

References 15

[1]	Kovacs G, Bartolome S, Denton CP, et al. Definition, classification and diagnosis of pulmonary hypertension[J]. Eur Respir J, 2024, 64:2401324.doi: 10.1183/13993003.01324-2024.
[2]	Beshay S, Sahay S, Humbert M. Evaluation and management of pulmonary arterial hypertension[J]. Respir Med, 2020, 171: 106099. doi: 10.1016/j.rmed.2020.106099.
[3]	Mocumbi A, Humbert M, Saxena A, et al. Pulmonary hypertension[J]. Nat Rev Dis Primers, 2024, 10:1. doi: 10.1038/s41572-023-00486-7.
[4]	Nair A, Pharmacologic therapy for pulmonary artery hypertension[J].Curr Opin Cardiol, 2020, 35:643-656. doi: 10.1097/hco.0000000000000796.
[5]	Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: a review[J]. JAMA, 2022, 327:1379-1391 doi: 10.1001/jama.2022.4402.
[6]	Hill NS, Gillespie MN, McMurtry IF. Fifty years of monocrotaline-induced pulmonary hypertension: what has it meant to the field?[J]. Chest, 2017, 152:1106-1108. doi: 10.1016/j.chest.2017.10.007.
[7]	Arnold ND, Pickworth JA, West LE, et al. A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension[J]. Nat Commun, 2019, 10:5183. doi: 10.1038/s41467-019-13139-9.
[8]	Cunningham CM, Li M, Ruffenach G, et al. Y-chromosome gene, Uty, protects against pulmonary hypertension by reducing proinflammatory chemokines[J].Am J Respir Crit Care Med, 2022, 206:186-196 doi: 10.1164/rccm.202110-2309OC.
[9]	Weng M, DM Baron DM, Bloch KD, et al. Eosinophils are necessary for pulmonary arterial remodeling in a mouse model of eosinophilic inflammation-induced pulmonary hypertension[J].Am J Physiol Lung Cell Mol Physiol, 2011, 301:L927-936 doi: 10.1152/ajplung.00049.2011.
[10]	Zhang L, Xu J, Zhou S, et al. Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma[J]. J Hepatol, 2024, 80:82-98. doi: 10.1016/j.jhep.2023.10.006.
[11]	Shi J, Zhou B, Tian Z, DOCK9 antisense RNA2 interacts with LIN28B to stabilize Wnt5a and boosts proliferation and migration of oxidized low densitylipoprotein-induced vascular smooth muscle cells[J].Bioengineered, 2022, 13:7564-7578. doi: 10.1080/21655979.2022.2033401.
[12]	Hu X, Sun Y, Wang S, et al. CircALMS1 alleviates pulmonary microvascular endothelial cell dysfunction in pulmonary hypertension[J].J Am Heart Assoc, 2024,13: e031867. doi: 10.1161/jaha.123.031867.
[13]	Gallardo-Vara E, Ntokou A, Dave JM, et al. Vascular path-obiology of pulmonary hypertension[J]. J Heart Lung Transplant, 2023, 42:544-552. doi: 10.1016/j.healun.2022.12.012.
[14]	Jandl K, Radic N, Zeder K, et al. Pulmonary vascular fibrosis in pulmonary hypertension-The role of the extracellular matrix as a therapeutic target[J].Pharmacol Ther, 2023, 247: 108438. doi: 10.1016/j.pharmthera.2023.108438.
[15]	Deng J, Wei RQ, Zhang WM, et al. Crocin's role in modulating MMP2/TIMP1 and mitigating hypoxia-induced pulmonary hypertension in mice[J]. Sci Rep, 2024, 14: 12716. doi: 10.1038/s41598-024-62900-8.